2026-01-02 - Analysis Report
Okay, let's break down the provided information for Recursion Pharmaceuticals Inc. (RXRX) and provide a comprehensive analysis.

**0) Report Structure**

We'll first present the raw data, then follow with a simple analysis of each section. Finally, we'll synthesize the findings into a comprehensive overview.

**1) Return Rate Comparison**

*   **Data:**
    *   Ticker: RXRX
    *   Company Name: Recursion Pharmaceuticals Inc
    *   Cumulative Return (RXRX): -33.76%
    *   Cumulative Return (VOO): 40.24%
    *   Divergence: -77.0 (Relative Divergence: 0.7)

*   **Company Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company industrializing drug discovery by decoding biology.

*   **Analysis:** RXRX has significantly underperformed the S&P 500 (VOO) over the period examined. The divergence is substantial (-77.0). The "relative divergence" of 0.7 suggests the current divergence is near the bottom of its historical range.

*   **Alpha, Beta Analysis Table:**

|            | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
| :--------- | :----- | :----- | :------ | :----- | :----- |
| 2022-2024  | 11.0%  | 99.5%  | -9.0%   | 2.3    | 3.5    |
| 2023-2025  | 9.0%  | 99.5%  | -53.0%   | 2.6    | 2.1    |

*   **Analysis of Alpha, Beta Table:**
    *   **CAGR:** The Compound Annual Growth Rate is positive but relatively low at 11% for 2022-2024 and 9% for 2023-2025.
    *   **MDD:** The Maximum Drawdown is extremely high at 99.5% in both periods, indicating massive peak-to-trough declines.
    *   **Alpha:** The Alpha is significantly negative, especially in the 2023-2025 period (-53.0%), meaning RXRX is dramatically underperforming its benchmark on a risk-adjusted basis.
    *   **Beta:** The Beta is high (2.3 and 2.6), indicating that RXRX's price is much more volatile than the overall market (S&P 500).
    *   **Cap:** Market Cap is decreasing.

**2) Recent Stock Price Fluctuations**

*   **Data:**
    *   Close: 4.09
    *   Last Market: Price: 4.09, Previous Close: 4.11, Change: -0.49%
    *   5-day SMA: 4.196
    *   20-day SMA: 4.454
    *   60-day SMA: 4.9225

*   **Analysis:** The stock is trading below all its short and medium-term moving averages. This suggests a downward trend in the short to medium term. The slight negative change in the last market indicates continued selling pressure.

**3) Index Indicators**

*   **Data:**
    *   MRI: 0.9 (High Investment Recommended)
    *   RSI: 33.0 (approaching oversold)
    *   PPO: -0.5268
    *   Hybrid Signal: Buy 100% (Very Safe - MRI: 0.90)
    *   Recent Relative Divergence Change: 0.7 (+) (short-term increase)
    *   Expected Return: 0.0%

*   **Analysis:**

    *   **MRI:** Although the MRI suggests high investment potential, it should be considered with caution given the underperformance of the stock as demonstrated by cumulative return divergence.
    *   **RSI:** An RSI of 33 is approaching oversold territory, which could indicate a potential for a short-term bounce.
    *   **PPO:** The negative PPO value reinforces the downward price trend.
    *   **Hybrid Signal:** The Buy signal from the hybrid model should be taken with extreme caution, considering all other negative factors.
    *   **Divergence Change:** The positive change in short-term relative divergence, coupled with an oversold RSI, indicates potential for a short-term price increase.
    *   **Expected Return:** An expected return of 0.0% suggests the model sees no long-term outperformance relative to the S&P 500.

**4) Recent News & Significant Events**

*   **News Summary:**

    *   **Negative:**
        *   RXRX Stock Plummet
        *   Stock fell 9% this week
        *   Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy.
    *   **Positive/Neutral:**
        *   Stock Surges on JPMorgan Upgrade, Trial Data Gains
        *   Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition
        *   Cathie Wood’s ARK Investment Buys 755K Shares

*   **Analysis:** The news flow is mixed. There are some positive catalysts (JPMorgan upgrade, trial data, ARK buying) but also negative headlines highlighting stock declines and alternative investment suggestions. The JPMorgan upgrade should be investigated to assess if it aligns with the high MRI score or if other factors are influencing it. The CEO Transition may be a good sign for the future, but in the meantime, current news is more influential to investors.

**4-2) Analyst Opinions**

*   **Data:**
    *   Mean Analyst Rating: No Key, suggesting unclear consensus.
    *   Number of Opinions: 7
    *   Target Price (Avg/High/Low): 7.00 / 11.00 / 3.00
    *   Recent Rating Changes: None provided.

*   **Analysis:** The analyst target price range is wide (3.00-11.00), suggesting significant disagreement on the stock's potential. The average target price of $7.00 is significantly above the current price, implying potential upside, but the lack of recent rating changes means this view may not be current.

**5) Recent Earnings Analysis**

*   **Data:**

| 날짜       | EPS    | 매출       |
| :--------- | :----- | :--------- |
| 2025-11-05 | -0.36  | 0.01 B$ |
| 2025-08-05 | -0.41  | 0.02 B$ |
| 2025-05-05 | -0.5   | 0.01 B$ |
| 2024-11-06 | -0.34  | 0.03 B$ |
| 2025-11-05 | -0.34  | 0.03 B$ |

*   **Analysis:** The company is consistently losing money, as evidenced by the negative EPS in each quarter. Revenue is low and inconsistent. This is a major concern.

**6) Financial Information**

*   **Data:**

*   **Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
| :--------- | :--------- | :------------ |
| 2025-09-30 | $0.00B     | -194.74%      |
| 2025-06-30 | $0.02B     | -5.54%        |
| 2025-03-31 | $0.01B     | -47.31%       |
| 2024-12-31 | $0.00B     | -183.62%      |
| 2024-09-30 | $0.03B     | 53.69%        |

*   **Capital and Profitability:**

| Quarter    | Equity     | ROE       |
| :--------- | :--------- | :-------- |
| 2025-09-30 | $1.05B     | -15.50%   |
| 2025-06-30 | $0.92B     | -18.70%   |
| 2025-03-31 | $0.93B     | -21.68%   |
| 2024-12-31 | $1.03B     | -17.29%   |
| 2024-09-30 | $0.52B     | -18.27%   |

*   **Analysis:** The revenue figures are low and volatile. The profit margins are generally very poor, with several quarters showing extremely negative percentages. The ROE is consistently negative, reflecting the company's inability to generate profits from its equity. The company's equity is relatively high, but the negative ROE raises concerns about the efficient use of capital.

**7) Comprehensive Analysis (Summary)**

*   **Overall Assessment:** RXRX presents a high-risk investment profile.
*   **Negative Factors:** Significant underperformance compared to the S&P 500, extremely high maximum drawdown, negative alpha, downward price trend, consistent losses (negative EPS), low and volatile revenue, poor profit margins, and negative ROE.
*   **Potentially Positive Factors:** Oversold RSI suggesting a possible short-term bounce, positive short-term relative divergence change, some positive news headlines (analyst upgrade, trial data, ARK investment), and a relatively high MRI (though this should be viewed skeptically given the other data).
*   **Recommendation:** Based on the data provided, a cautious approach is warranted. The fundamental financials (profitability) are concerning. Any investment should be considered highly speculative, and thoroughly researched. While some indicators suggest a possible short-term rebound, the overall picture points to significant risk.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.